Myeloid malignancies caused by U2AF1 mutations express “active” IRAK4 isoforms, which may be therapeutically targeted. In MDS and AML, this activation, in turn, triggers innate immune pathways (25). This evidence concerns the gene U2AF1 and acute myeloid leukemia.